Synergism of calycosin and bone marrow-derived mesenchymal stem cells to combat podocyte apoptosis to alleviate adriamycin-induced focal segmental glomerulosclerosis

This publication has 62 references indexed in Scilit:

• Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis
  American Journal of Nephrology, 2018
• Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
  American Journal of Physiology-Renal Physiology, 2018
• Preconditioning influences mesenchymal stem cell properties in vitro and in vivo
  Journal of Cellular and Molecular Medicine, 2018
• Mesenchymal Stem Cell-Based Therapies against Podocyte Damage in Diabetic Nephropathy
  Tissue Engineering and Regenerative Medicine, 2017
• Unwinding focal segmental glomerulosclerosis
  F1000Research, 2017
• Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy
  Journal of Diabetes Research, 2017
• Toll-like Receptor 9 Can be Activated by Endogenous Mitochondrial DNA to Induce Podocyte Apoptosis
  Scientific Reports, 2016
• Astragalus (a traditional Chinese medicine) for treating chronic kidney disease
  Cochrane Database of Systematic Reviews, 2014
• Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria
  Clinical and Experimental Nephrology, 2013
• Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential
  Blood, 2004